Kyung Sook Kim – CEO, Corestem, South Korea
Dr Kyung Sook Kim, CEO of Corestem, explains how her company has been pioneering the Korean stem cell industry since its foundation in 2003. She also discusses reimbursement and regulation…
The Korea Medical Devices Industry Association (KMDIA) is a trade association committed to improving public health and development of the industry by advocating companies that manufacture, import, export, or sell medical devices since its foundation in 1999.
The Association has around 750 members, bringing these companies together to share information and experience to disseminate the latest technologies and facilitate access to high-quality, affordable medical devices in Korea. The KMDIA is a valuable partner to government authorities such as the Ministry of Health and Welfare and the Ministry of Food and Drug Safety actively presenting policy proposals and regulation ideas, while offering extensive support to Korean medical devices manufacturers compete and grow further in the global market.
The medical devices industry continues rapid growth despite economic slowdown across the world. The factors that drive such growth include: aging society, growing anti-aging industry as a result of higher income, greater interest in health and wellness, government policies that value higher standard of life, emerging latest technologies and biomedical innovation. The Korean government designated the medical devices industry as one of its priority “growth engines” aspiring to lift Korea to global top 5 in the industry by 2018.
The Association also supports foreign and multi-national medical devices companies by providing market intelligence and statistics while assisting them in regulatory and approval procedures. Local and foreign firms are brought together to enter into business discussion and invited to exhibitions hosted by the KMDIA. The MOUs with the counterparts in different regions, such as AdvaMed and EucoMed, are part of the efforts to build networks and promote interactions among member companies, to eventually promote Korea as an attractive market.
The KMDIA is a dedicated partner to all members who seek assistance and partnership.
Contact details:
8~9F, Yeosam Bldg, 123 Teheran-ro, Gangnam-gu, Seoul Korea (135-748)
Tel: +82 2 596 7404
Fax: +82 2 596 7401
kmdia@kmdia.or.kr
www.kmdia.or.kr
Dr Kyung Sook Kim, CEO of Corestem, explains how her company has been pioneering the Korean stem cell industry since its foundation in 2003. She also discusses reimbursement and regulation…
Dr Jino Park, founder and CEO of P&K Skin Research Centre, offers his assessment of the success of the Korean pharmaceutical industry, and the potential cosmetic products of the future.…
Ji-Young Lee, senior director clinical operations, and general management & business administration Korea of PAREXEL Korea discusses the strengths of Korea’s clinical research environment, and how PAREXEL can leverage its…
* This interview was conducted before GE’s announcement of its divestment of the GE Biopharma business Francis Van Parys, president & CEO of GE Healthcare Korea discusses their ambitions to…
Young Kim, founder and CEO of Synex Consulting Ltd., a consulting firm assisting healthcare companies in introducing and marketing their products on the Korean market, discusses how Synex’s ICC (In-Country…
Min-Young Kim, general manager at Ipsen Korea discusses her strategy to refocus the Korean affiliate away from the toxin market and towards oncology and rare diseases. She also documents Ipsen’s…
Woosok Lee, CEO of Kolon Pharma, Kolon Life Science and Kolon TissueGene, offers his insights into the potential of their blockbuster product Invossa which could exceed USD five billion of…
Dr Jin San-Yoo, president and CEO of PharmAbcine, lifts the lid on the company’s combination therapy with MSD’s blockbuster oncology treatment Keytruda. Dr Yoo explains the rationale behind his decision…
Professor Dae Ho Lee has been researching and treating Korean cancer patients for more than 20 years and advises the current government on healthcare policy. He breaks down the benefits…
This week the Korean Ministry of Food and Drug Safety announced that as of 12th March 2019 a revised narcotics bill will go into effect that will allow imports of medical…
Dr Byung Guk Yang, CEO of Daewoong Bio, explains the challenges the Korean healthcare system is facing and how his experience in the public sector now helps him lead a…
YJ Kim, country manager at BD Korea, discusses the integration of Bard into BD at the local level. He also offers his insights into the challenges of approval and pricing…
See our Cookie Privacy Policy Here
